Dr. Joffe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
530 East 74th
MSKCC-Koch
New York, NY 10021Phone+1 646-608-3703Fax+1 929-321-8156
Summary
- I am a lymphoma specialist, hemato-oncologist and biomedical informatician. I specialize in treating all types of lymphoma, and have a special research focus on follicular, small lymphocytic, marginal zone, and mantle cell lymphomas. I also have extensive experience in treating more aggressive types, such as Diffuse-Large B-cell, Hodgkin’s, and Burkitt’s lymphomas. I am grateful and honored to be part of MSK’s lymphoma team, delivering the most cutting-edge care to our patients.
Education & Training
Tel Aviv University SacklerClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2018 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Oct 24
- A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Start of enrollment: 2017 Dec 28
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Apr 03
Publications & Presentations
PubMed
- 86 citationsPhase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2021-06-25 - 36 citationsClinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-EraSabela Bobillo, Erel Joffe, Jessica A. Lavery, David Sermer, Paola Ghione
Blood. 2021-01-07 - 92 citationsFollicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie Lee Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith
Blood Cancer Journal. 2020-07-17
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaErel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Professional Memberships
- Member
- Member
- European Hematology AssociationMember
Other Languages
- Hebrew
Industry Relationships
- Advisory Board, Epizyme2020 - Present
- Advisory board, AstraZeneca2020 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
